Strategic Advisors LLC Abb Vie Inc. Transaction History

Strategic Advisors LLC

$530 Million
Q3 2024

A detailed history of Strategic Advisors LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Strategic Advisors LLC holds 54,282 shares of ABBV stock, worth $9.77 Million. This represents 2.02% of its overall portfolio holdings.

Number of Shares

54,282

Previous 59,066 8.1%

Holding current value

$9.77 Million

Previous $10.1 Million 5.8%

% of portfolio

2.02%

Previous 1.99%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$163.84 - $199.33 $783,810 - $953,594	-4,784 Reduced 8.1%	54,282 $10.7 Million
Q2 2024 Jul 11, 2024	SELL	$154.79 - $180.76 $787,726 - $919,887	-5,089 Reduced 7.93%	59,066 $10.1 Million
Q1 2024 Apr 19, 2024	BUY	$159.82 - $182.1 $579,826 - $660,658	3,628 Added 5.99%	64,155 $11.7 Million
Q4 2023 Jan 19, 2024	SELL	$137.6 - $154.97 $2.47 Million - $2.78 Million	-17,929 Reduced 22.85%	60,527 $9.38 Million
Q3 2023 Oct 13, 2023	BUY	$133.59 - $154.65 $215,747 - $249,759	1,615 Added 2.1%	78,456 $11.7 Million
Q2 2023 Jul 31, 2023	SELL	$132.51 - $164.9 $108,658 - $135,218	-820 Reduced 1.06%	76,841 $10.4 Million
Q1 2023 Apr 27, 2023	BUY	$144.61 - $166.54 $144,320 - $166,206	998 Added 1.3%	77,661 $12.4 Million
Q4 2022 Jan 23, 2023	SELL	$138.31 - $165.87 $420,739 - $504,576	-3,042 Reduced 3.82%	76,663 $0
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $5,502 - $6,311	-41 Reduced 0.05%	79,705 $10.7 Million
Q2 2022 Aug 03, 2022	SELL	$137.62 - $174.96 $179,043 - $227,622	-1,301 Reduced 1.61%	79,746 $12.2 Million
Q1 2022 May 10, 2022	SELL	$131.98 - $163.75 $381,026 - $472,746	-2,887 Reduced 3.44%	81,047 $13.1 Million
Q4 2021 Jan 21, 2022	BUY	$107.43 - $135.93 $641,679 - $811,909	5,973 Added 7.66%	83,934 $11.4 Million
Q3 2021 Oct 21, 2021	BUY	$106.4 - $120.78 $1.57 Million - $1.78 Million	14,712 Added 23.26%	77,961 $8.41 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $65,861 - $73,373	626 Added 1.0%	63,249 $7.12 Million
Q1 2021 May 05, 2021	BUY	$102.3 - $112.62 $790,779 - $870,552	7,730 Added 14.08%	62,623 $6.78 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $307,793 - $415,554	3,824 Added 7.49%	54,893 $5.86 Million
Q3 2020 Oct 13, 2020	BUY	$85.91 - $100.83 $38,058 - $44,667	443 Added 0.88%	51,069 $4.49 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $1.69 Million - $2.26 Million	22,975 Added 83.09%	50,626 $4.95 Million
Q1 2020 Apr 30, 2020	BUY	$64.5 - $97.79 $436,471 - $661,744	6,767 Added 32.4%	27,651 $2.17 Million
Q4 2019 Feb 05, 2020	BUY	$72.13 - $90.25 $336,270 - $420,745	4,662 Added 28.74%	20,884 $1.85 Million
Q3 2019 Oct 17, 2019	BUY	$62.98 - $75.72 $583,572 - $701,621	9,266 Added 133.21%	16,222 $1.23 Million
Q2 2019 Jul 22, 2019	SELL	$65.7 - $83.98 $15,636 - $19,987	-238 Reduced 3.31%	6,956 $505,000
Q1 2019 Apr 15, 2019	SELL	$77.14 - $90.79 $824,780 - $970,726	-10,692 Reduced 59.78%	7,194 $580,000
Q4 2018 Jan 24, 2019	SELL	$77.85 - $96.01 $52,393 - $64,614	-673 Reduced 3.63%	17,886 $1.65 Million
Q3 2018 Oct 18, 2018	SELL	$88.91 - $98.84 $166,884 - $185,522	-1,877 Reduced 9.18%	18,559 $1.76 Million
Q2 2018 Jul 30, 2018	SELL	$89.78 - $106.23 $2.31 Million - $2.74 Million	-25,784 Reduced 55.79%	20,436 $1.89 Million
Q1 2018 Apr 19, 2018	BUY	$92.01 - $123.21 $6,072 - $8,131	66 Added 0.14%	46,220 $4.38 Million
Q4 2017 Jan 16, 2018	SELL	$89.56 - $98.21 $70,841 - $77,684	-791 Reduced 1.68%	46,154 $4.46 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $29,057 - $37,115	416 Added 0.89%	46,945 $4.17 Million
Q2 2017 Aug 10, 2017	BUY	N/A	46,529	46,529 $3.37 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Advisors LLC with notifications on news.

Account

Strategic Advisors LLC Abb Vie Inc. Transaction History